Investor Relations
We invite all current and prospective shareholders, partners, and other
interested parties to browse our web site to learn more about the exciting
developments at our company. Investor inquires can be directed to
Michael Barr at
519-858-5157.
Why Invest in Critical
Outcome Technologies Inc.?
COTI is positioned to help build the pipeline
and increase revenue for all sizes of
pharmaceutical companies
In recent years large pharmaceutical companies have been experiencing slowing
sales growth due to declining pipeline productivity and increasing patent
expirations. For example, approximately 30 brand-name drugs have lost their
patents in 2006, resulting in a total loss of $20 billion in sales. In 2007 this
figure is projected to be $16 billion. This comes at the worst possible time
because Big Pharma is at a 25-year low in new drug approvals (IMS Health).
COTI is positioned to decrease the cost and
time associated with new drug development.
The 2006 Industry Report of the Pharmaceutical Research and Manufacturers of
America (“PRMA”) reports that it takes 10-15 years and costs US$800 million for
a drug to be successfully introduced for patient use. Traditionally, during drug
discovery and pre-clinical pharmaceutical companies evaluate 5,000 or more
compounds for every single successful FDA approval. The PRMA report also
suggests that only 3 of 10 marketed drugs ever produce revenues that match or
exceed R&D costs. Partners who license a COTI targeted library can potentially
reduce 2-4 years off the current pre-clinical drug development timeline.
